The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year forecast period. One of these novel therapies is Yescarta, the first chimeric antigen receptor (CAR) T-cell therapy; it is approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and represents a significant milestone in NHL drug development. Offsetting this market growth will be the biosimilar erosion expected for rituximab, the patient-, and market-share leader in 2017 in the NHL space, and the generic erosion of Revlimid (and, to a lesser extent, bendamustine). Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 20 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.
Epidemiology: Diagnosed incidence of follicular lymphoma (FL) (including transformed FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), DLBCL, and mantle cell lymphoma (MCL).
Population segments in market forecast: First line, second line, and third/fourth line for FL, CLL/SLL, DLBCL, and MCL.
Emerging therapies: Phase I and II: 45 drugs; Phase III: 10 drugs; registered: 5 drugs.